Researchers led by St. Jude Children’s Research Hospital have identified a genetic variation associated with influenza severity and the supply of killer T cells that help patients fight the infection.
Researchers at Johns Hopkins Medicine report evidence that zebrafishes’ natural ability to regenerate their eyes’ retinal tissue can be accelerated by controlling the fishes’ immune systems. Because evolution likely conserved this mechanism of regenerative potential in other animals, the new findings may one day advance efforts to combat degenerative eye disease damage in humans.
As published in JNCCN, a University of Michigan Comprehensive Cancer Center study found that adherence to distress screening protocols set by the Commission on Cancer could lead to 18% fewer ER visits and 19% fewer hospitalizations.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia
Bugs in your eyes may be a good thing. Resident microbes living on the eye are essential for immune responses that protect the eye from infection, new research shows. The study, which appears in the journal Immunity on July 11, demonstrates the existence of a resident ocular microbiome that trains the developing immune system to fend off pathogens. The research was conducted at the National Eye Institute (NEI), part of the National Institutes of Health.
A new study led by Washington University School of Medicine in St. Louis has found that viruses in the intestines may affect a person’s chance of developing Type I diabetes. Children whose gut viral communities are less diverse are more likely to generate self-destructive antibodies that can lead to Type 1 diabetes. Further, children who carried a specific virus belonging to the Circoviridae family were less likely to develop diabetes than those who carried members of a different group of viruses.
Three case reports published in the New England Journal of Medicine demonstrate the promise of cancer immunotherapy in gray zone lymphoma, potentially paving the way for clinical trials utilizing this strategy in this and related conditions.
Dr. Nicole N. Scheff Receives $120,000-Plus NIDCR F32 Grant to investigate whether immune cells in the oral cancer environment contribute to sex differences in oral cancer pain.
Combination therapy with two immunotherapy drugs produces an unprecedented doubling of response rates from 20 percent to 40 percent, a new study shows.
Developing probiotics and nutraceuticals that improve the health of animals and human will be part of the research accomplished through the new South Dakota Center for Biologics Research and Commercialization.
Scientists have solved the structure of a protein that helps a common respiratory virus evade the immune system. The team, led by researchers at Washington University School of Medicine in St. Louis, have identified critical parts of the protein that could be targeted with drugs or vaccines, opening up the possibility of preventing or treating an infection that sickens thousands of babies and elderly people every year.
Researchers at the Cornell University College of Veterinary Medicine have discovered a new method to measure tiny amounts of antibodies in foals, a finding described in the May 16 issue of PLOS ONE. The methodology will help understand how fast a foal starts producing its own antibodies, which in turn will help optimize recommendations for young horse vaccination schedules, said Dr. Julia Felippe, associate professor of large animal medicine, and research associate Rebecca Tallmadge.
A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks.
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.
Medicinal payload could be delivered by engineered RNAs that can be controlled by a billion year-old “genetic fossil” found in all cells
$400k grant to Johns Hopkins University School of Medicine investigator Cynthia Sears will carry out research aimed at improving effectiveness of immunotherapy in patients with colorectal cancer.
By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs. The “proof of concept” findings, published online Feb. 13, 2017, in Clinical Cancer Research, point to distinct variations not in the genetic code of each tumor sample, but in the expression levels of certain proteins encoded by normal genes.
St. Jude Children’s Research Hospital discovery of the mechanism of T cell exhaustion will lead to treatments to enhance immunotherapies against cancers and such viruses as HIV
$1 million CRI Technology Impact Award will support UPENN investigator's development of microchip-based research models that mimic human cancer and immune cell interactions
Until recently, melanomas that had spread to the brain could only be treated with surgery and radiation therapy. And even with treatment, patients typically lived only a median of four months. However, patients like Kathy Roberts now have alternatives. After having surgery to repair the damage from the tumors in her ankle, her doctors encouraged her to enroll in a clinical trial of immunotherapy for patients with melanoma brain tumors at Georgetown Lombardi Comprehensive Cancer Center, which she did.
In the journal Nature Nanotechnology, University of North Carolina Lineberger Comprehensive Cancer Center researchers report on strides made in the development of a strategy to improve the immune system's detection of cancer proteins by using “sticky” nanoparticles.
Researchers at the University of Pittsburgh and the University of Toronto have uncovered the first molecular steps that lead to immune system activation and eventual rejection of a transplanted organ.
The Focused Ultrasound Foundation (FUSF) and the Cancer Research Institute (CRI) are establishing a partnership with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments. Both organizations recognize the intersection of the latest developments in FUS therapy and cancer immunotherapy offers a highly promising opportunity for combination approaches to treat a variety of cancers.
St. Jude Children’s Research Hospital and Fred Hutchinson Cancer Research Center have developed an algorithm that predicts T cell recognition of antigens and sets the stage to more effectively harness the immune system
Researchers have found the first direct evidence that autoimmunity plays a role in Parkinson’s disease, suggesting that immunosuppressants might play a role in treatment.
CRI's 2017 Immunotherapy Patient Summit Series will travel to five U.S. cities to provide free educational programming designed for cancer patients and caregivers who are seeking to learn more about cancer immunotherapy and clinical trials.
Researchers have for the first time discovered that a specific type of irritable bowel syndrome is associated with exhaustion of the immune system in patients.
— Jorge Henao-Mejia, MD, PhD, an assistant professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia, has been recognized by The Pew Charitable Trusts as one of its 22 national Pew Scholars in Biomedical Sciences.
One in three people has a potentially nasty parasite hiding inside their body -- tucked away in tiny cysts that the immune system can’t eliminate and antibiotics can’t touch. But new research reveals clues about how to stop it: Interfere with its digestion during this stubborn dormant phase.
In recent years, immunotherapy, a new form of cancer therapy that rouses the immune system to attack tumor cells, has captivated the public’s imagination. When it works, the results are breathtaking. But more often than not it doesn’t, and scientists still don’t know why.
Researchers have discovered a clue that could unlock the potential of immunotherapy drugs to successfully treat more cancers. The findings, published in Cell, were made in mice and showed that targeting a sub-population of immune cells called regulatory T cells could be an effective approach to treating cancers. The findings also point to what could be an important mechanism by which current immunotherapy drugs work, providing clues to making them more effective.
Being able to quiet active neutrophils with a dual-beam laser could lead to new treatments for lung injury.
Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. Scientists have found up to 30 percent of adult ALL patients have what’s called a Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients exposed to standard treatments often see high relapse rates, and treatment-related deaths remain high. But researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered new science, published this week in the journal Leukemia, that could provide better therapeutic options for patients.
In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda).
Profs. Michal Schwartz and Ido Amit at the Weizmann Institute of Science have discovered a unique immune cell type whose regulated activation may form the foundation of a future treatment for Alzheimer’s disease
Patients who receive the standard surgical treatment for melanoma that has spread to one or more key lymph nodes do not live longer, a major new study shows.
Houston Methodist is launching the Center for Immunotherapy Research under the leadership of Shu-Hsia Chen, Ph.D., a cancer immunotherapy researcher recruited from Icahn School of Medicine at Mount Sinai.
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck.
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice. Experiments with the tiny, double-duty "immunoswitch" found it able to dramatically slow the growth of mouse melanoma and colon cancer and even eradicate tumors in test animals, the researchers report.
Day-long endurance event starting at the U.S. Military Academy at West Point, NY, focused on cancer immunotherapy research
Studying mice, researchers at Washington University School of Medicine in St. Louis have shown that a natural sugar called trehalose revs up the immune system’s cellular housekeeping abilities. These souped-up housecleaners then are able to reduce atherosclerotic plaque that has built up inside arteries. Such plaques are a hallmark of cardiovascular disease and lead to an increased risk of heart attack.
Dr. Kunle Odunsi of Roswell Park Cancer Institute presented an update about an ongoing clinical trial involving T-cell engineering to treat advanced ovarian cancer at the ASCO Annual Meeting in Chicago.
Roswell Park and OmniSeq report that a custom algorithm they developed based on a 54-gene signature accurately predicted response to anti-PD-L1 treatment in 90% of the cases they analyzed.
A research study led by University of Minnesota engineers gives new insight into how cancer cells move based on their ability to sense their environment. The discovery could have a major impact on therapies to prevent the spread of cancer. The same research also could be used to improve regenerative medicine.
Scientists recognized for seminal discoveries in cancer’s ability to thwart immune surveillance that paved the way to immune-based cancer therapies
The study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.
A recent study by Yale Cancer Center researchers revealed a 41% response to the antibody drug, enfortumab vedotin, by metastatic urothelial (mUC) tumors in a phase I clinical trial
Immunotherapy trial in metastatic triple negative breast cancer patients proves to shrink tumors in patients.
Immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as a preoperative treatment shows promise in early stage TNBC.
The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects. The findings will be presented by Dr. Seth Pollack, a physician-scientist at Fred Hutchinson Cancer Research Center, June 5 in a poster at the American Society of Clinical Oncology annual meeting in Chicago.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right